GSK Commences $10.6 Billion All-Cash Tender Offer for Nuvalent at $124.00 Per Share

summarizeSummary

GSK has formally launched its all-cash tender offer to acquire Nuvalent, Inc. for $124.00 per share, with the Nuvalent board unanimously recommending the offer.

check_boxKey Events · M&A and Partnerships · NUVL

• Tender Offer Commenced

  GSK, through its subsidiary Harmony Row Acquisition Co., has formally commenced an all-cash tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share.

• Board Recommendation

  Nuvalent's Board of Directors unanimously determined the merger agreement and the tender offer are advisable and in the best interests of the company and its shareholders, recommending they tender their shares.

• Transaction Details

  The total transaction valuation is approximately $10.6 billion. The offer is not subject to a financing condition, with GSK securing an $11 billion facility.

• Shareholder Support

  Supporting stockholders, including Deerfield and certain directors and officers, collectively owning approximately 28% of all outstanding shares, have agreed to tender their shares.

auto_awesomeAnalysis · NUVL · Life Sciences

This filing marks the formal commencement of GSK's tender offer to acquire Nuvalent, Inc. for $124.00 per share in an all-cash transaction. The offer price is slightly above Nuvalent's current trading price, which is near its 52-week high, providing a clear exit for shareholders. The acquisition, valued at approximately $10.6 billion, represents a significant event for Nuvalent, transitioning it from a public company to a subsidiary of GSK. The unanimous recommendation by Nuvalent's board and the commitment from major shareholders to tender their shares indicate strong internal support for the deal.